The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- Requests for Frequent Delivery Abating in Tohoku: Wholesalers
March 28, 2011
- Oncology Strategies of Top-four Japanese Pharmaceutical Companies
March 28, 2011
- Nichi-Iko Acquires Additional Shares from Aprogen
March 28, 2011
- JSMI Presents List of OTC Drugs Available Free of Charge
March 28, 2011
- Takeda Suspends PII Trial for Anti-obesity Drug in US
March 28, 2011
- 14 Hokoku-hinmoku Included in NHI Price List
March 28, 2011
- MTPC Ties Up with Kyoto Univ. to Develop Drugs for Kidney Disease
March 28, 2011
- Korosho Calls For Reasonable Ordering Practices from Med. Institutions, Pharmacies
March 28, 2011
- JMA to Dispatch JMATs to Disaster Area
March 28, 2011
- Both AZ, Plaintiffs Appeal to High Court
March 28, 2011
- NIRS Dispatches 3 Teams to Fukushima
March 28, 2011
- JAMS to Promote Industry-Academia Alliances by Increasing COI Transparency
March 28, 2011
- Insulin Manufacturers Ensure Stable Supply of Their Products
March 28, 2011
- Astellas Applies for Marketing Approval for Bixalomer
March 28, 2011
- Domestic, Foreign Drugmakers Up Efforts to Assist Quake Victims
March 28, 2011
- Wholesalers Striving to Fulfill Mission despite Risk
March 28, 2011
- Exal Approved for LCH as Additional Indication: Nippon Kayaku
March 28, 2011
- 2 Treatments Recommended for Approval as Senshin-iryo
March 28, 2011
- Gas Shortage Hurting Distribution in Tohoku: Wholesalers
March 28, 2011
- Higher Dosage Approved for Meropen: DSP
March 28, 2011
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…